Xiamen Amoytop Biotech announced that the company has signed a 'Technology Licensing and Development Cooperation Agreement' with Tengji Medicine, obtaining the exclusive license for NM6606 and related intellectual property in China, for the treatment of liver fat metabolism and liver fibrosis-related diseases. The agreement stipulates that the company will pay an initial payment of 10 million yuan after the agreement takes effect, a maximum of 0.135 billion yuan for development and sales milestone payments, and pay a certain percentage of annual net sales as royalty fee.